COVID-19 treatments

Last updated June 8, 2021.

Available languages: Español | Tiếng Việt | 中文 | Soomaali | العربية

Overview

COVID-19 monoclonal antibodies are neutralizing antibody treatments available to people who have tested positive for COVID-19, exhibit mild to moderate symptoms of the disease, and who are at high risk of developing severe COVID-19. 

Monoclonal antibody treatments involve the administration of a combination of monoclonal antibody products, either bamlanivimab in combination with etesevimab or casirivimab in combination with imdevimab. 

Monoclonal antibody treatments have been authorized for those individuals with an onset of symptoms within 10 days, who are not hospitalized, but are at high risk of developing severe COVID-19. 
The following medical conditions or other factors may place adults and pediatric patients (age 12-17 years and weighing at least 40 kg) at higher risk for progression to severe COVID-19:

  • Older age (≥65 years).
  • Obesity or being overweight (for example, adults with BMI >25 kg/m, or if age 12-17, have BMI ≥85th percentile for their age and gender based on CDC growth charts).
  • Pregnancy.
  • Chronic kidney disease.
  • Diabetes.
  • Immunosuppressive disease or immunosuppressive treatment.
  • Cardiovascular disease (including congenital heart disease) or hypertension.
  • Chronic lung diseases (for example, chronic obstructive pulmonary disease, asthma [moderate-to-severe], interstitial lung disease, cystic fibrosis and pulmonary hypertension).
  • Sickle cell disease.
  • Neurodevelopmental disorders (for example, cerebral palsy) or other conditions that confer medical complexity (for example, genetic or metabolic syndromes and severe congenital anomalies).
  • Having a medical-related technological dependence (for example, tracheostomy, gastrostomy, or positive pressure ventilation not related to COVID-19).

Other medical conditions or factors (for example, race or ethnicity) may also place individual patients at high risk for progression to severe COVID-19 and authorization of monoclonal antibody treatment under the EUA is not limited to the medical conditions or factors listed above. Visit the CDC's website for additional information on medical conditions and factors associated with increased risk for progression to severe COVID-19. Healthcare providers should consider the benefit-risk for an individual patient. 

Monoclonal antibody treatments are not indicated for use on those who are hospitalized or on oxygen for COVID-19 treatment.

If you have tested positive for COVID-19 and you are an individual at high risk of developing severe COVID-19 due to your age or  medical condition, contact your provider to see if you are eligible for monoclonal antibody treatment. These are outpatient treatments, administered intravenously at hospitals, outpatient infusion centers and clinics. Each treatment requires one infusion, administered over an hour or less, followed by one hour of monitoring. The medications are free, and administration fees are paid for through Medicaid, Medicare, and many health insurance plans.

FAQ

Extending all Coloradans access to COVID-19 monoclonal antibody treatment is a goal and priority. Therefore, we have reached out to hospitals, infusion centers, and clinics statewide to identify their interest and capacity to administer these treatments. 

To ensure equitable access, if the demand for monoclonal antibody treatment was to exceed the available supply, the Department has built an online software tool that can be adjusted to help fairly allocate treatment if needed. Currently, all eligible patients entered into the tool are selected for treatment.

The Department is building communication tools so Coloradans with mild to moderate COVID-19 can learn if these therapies are right for them. The Department is continuing to explore ways to provide outreach to the general public.

Check to see if you are eligible for COVID-19 monoclonal antibody treatment based on your COVID-19 test, your onset of symptoms and your medical condition. If you are eligible, contact your healthcare provider.

Your healthcare provider can assess your symptoms, discuss the benefits and risks of monoclonal antibody treatment, and determine your eligibility to receive it.  If you agree to receive the treatment, your healthcare provider will write a prescription for you. Your healthcare provider (physician, advance practice nurse with prescriptive authority, and physician assistants) may then enter the prescription into the Department online software tool and you will be contacted by the hospital, infusion site or clinic to schedule the treatment. Or, your healthcare provider may provide you with a prescription for monoclonal antibody treatment and you will select and contact an infusion site to administer the treatment. 

The University of Colorado has information for all Coloradans with questions about monoclonal antibody treatment.

All infusion sites seeking a supply of COVID-19 monoclonal antibody products must order the products directly from AmerisourceBergen Corporation (ABC), the sole distributor of these products.

Download information on how to order from ABC.

The products are free of charge to requesting sites.

Step 1

Determine that your patient meets the eligibility criteria to receive the product. Eligible patients are those who are:

  1. Symptomatic with less than 10 days since symptom onset AND 
  2. At high risk.
    • The following medical conditions or other factors may place adults and pediatric patients (age 12-17 years and weighing at least 40 kg) at higher risk for progression to severe COVID-19:
      • Older age (≥65 years).
      • Obesity or being overweight (for example, adults with BMI >25 kg/m, or if age 12-17, have BMI ≥85th percentile for their age and gender based on CDC growth charts).
      • Pregnancy.
      • Chronic kidney disease.
      • Diabetes.
      • Immunosuppressive disease or immunosuppressive treatment.
      • Cardiovascular disease (including congenital heart disease) or hypertension.
      • Chronic lung diseases (for example, chronic obstructive pulmonary disease, asthma [moderate-to-severe], interstitial lung disease, cystic fibrosis and pulmonary hypertension).
      • Sickle cell disease.
      • Neurodevelopmental disorders (for example, cerebral palsy) or other conditions that confer medical complexity (for example, genetic or metabolic syndromes and severe congenital anomalies).
      • Having a medical-related technological dependence (for example, tracheostomy, gastrostomy, or positive pressure ventilation not related to COVID-19).
    • Other medical conditions or factors (for example, race or ethnicity) may also place individual patients at high risk for progression to severe COVID-19 and authorization of monoclonal antibody treatment under the EUA is not limited to the medical conditions or factors listed above. Visit the CDC's website for additional information on medical conditions and factors associated with increased risk for progression to severe COVID-19. Healthcare providers should consider the benefit-risk for an individual patient.
  3. Have a positive Sars-CoV-2 PCR OR any antigen test that detects specific proteins from the virus

This treatment is not authorized for use in patients 

  • who are hospitalized due to COVID-19, OR
  • require oxygen therapy due to COVID-19, OR
  • require an increase in baseline oxygen flow rate due to COVID-19 in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity
Step 2

Decide which process you would like to follow in order for your patient to receive treatment. There are two processes available.

  • Complete the COVID-19 Monoclonal Antibody Connector tool 
    • The final page of the monoclonal antibody connector tool includes a list and map of current infusion sites registered with the state. You and your patient can select the patient’s closest or preferred location to receive treatment. The infusion site will be notified of the selection and will contact the patient to schedule treatment.
    • If the site selected is unable to accommodate your patient, you will be notified by the infusion site to select another location. When you have done so, you must notify the original infusion site in order for the patient’s record to be transferred to the new treatment location.
  • Provide your patient with a prescription for monoclonal antibody  treatment and inform the patient of the location of potential infusion sites the patient may contact to receive treatment.

Eligibility Determination

Open Embed